Anonymizing a Mammoth Growth Engagement Into a Serialized MAC Field Study
The question
Is there an existing Mammoth Growth client engagement (Progress, Nutrafol) that could anonymize into a serialized field study? The case-study version of Mechanic 5 is more credible than the synthetic version. (Source: project, High priority. Derivative of [[2026-05-11-practitioner-newsletter-acquisition-tactics.md]].)
What we already know (from the vault)
- The MG engagement is the strongest single body of operational evidence the founder has. 11 clients, 24 projects, 6,866 billable hours from 2022-2026. Nutrafol alone: 4+ years, 6 SOWs, 3,378 hours (multi-year longest-client run). Progress Software: where the MAC framework's canonical case study was built. See [[2026-05-05-sendoff-testimonials]] and [[01-projects/mammoth-growth/index]].
- The MAC canonical case study is already a Progress engagement, named explicitly in the vault.
apps/dbt-edw/models/03_gold/opp_renewals/gold_opp_pipeline.sqlis the load-bearing example — 30+ columns, 3 source systems, PRO-303 dual-path override pattern, demonstrates the 14-tests-existing → 95-tests-MAC gap. This is the artifact RDCO already uses to teach MAC. See [[2026-04-13-gold-opp-pipeline-mg-progress]]. - The MAC landing page spec already imposes a no-confidential-content rule. Build spec includes a grep audit blocking "Mammoth", "Progress", "gold_opp_pipeline", "silver_fct_*", "Nutrafol". This means the published artifact must be either fully anonymized or built from synthetic data. See [[2026-05-05-build-spec]].
- Send-off testimonials confirm MG senior leadership endorses the agentic-process work. Dylan Cruise on record: "Ben architected, built, internally advocated for, trained the team on, and operationalized the agentic harness that 'transformed how we go to market and deliver for all of our clients.'" Tom Clinton on record: "foundational work in all of the agentec processes that we've built." Standing return offer from Tom + Jeff Bartolini. See [[2026-05-05-sendoff-testimonials]].
- The internal-review on cc-wrapped + MG harness work is filed. Governs IP boundary on what the founder authored vs MG-owned. Settled cleanly Apr 23. See [[internal-review-mg-harness-cc-wrapped-2026-04-13]].
- Practitioner-newsletter brief named this question as a high-leverage follow-up. "The case-study version of Mechanic 5 is more credible than the synthetic version" — Mechanic 5 being "case study with named numbers." Brief at [[2026-05-11-practitioner-newsletter-acquisition-tactics]].
- The bet-architecture playbook treats the Progress engagement as the live MAC instrumentation. "Sensors: founder's Progress engagement is the live instrumentation. Documentation in [client-confidential] form already exists; anonymized version is the publishable artifact." See [[2026-04-30-rdco-bet-architecture-playbook]].
What the web says
- Mammoth Growth has already published Nutrafol publicly as a named case study. Their
/proofpage lists "Customer Clarity — Grew revenue 60% in one year and achieved a successful exit" (the Nutrafol/Unilever 2022 outcome). The Nutrafol case study URL (mammothgrowth.co.uk/case-study/nutrafol) currently 301-redirects to metrongrowth.com/work — suggesting an active rebrand or domain consolidation in progress, but the case study existed as published collateral. - MG's named-client stack on Nutrafol is on-record. Mixpanel + Segment (CDP) + Iterable + Snowflake + dbt + Tableau. Pre-existing siloed sources: Magento, Friendbuy, Unbounce, Zendesk. 60% revenue surge → Unilever acquisition 2022. This is MG's public version, not RDCO's.
- Datafold also published a Nutrafol case study (datafold.com/case-study/nutrafol). Multiple vendors have already published this client publicly, which lowers the marginal cost of RDCO referencing the engagement at the "public-knowledge" tier.
- Magecom published an e-commerce case study on Nutrafol (magecom.net/case-study/nutrafol). Three different vendors have published Nutrafol case studies. Nutrafol is comfortable being named publicly.
- Standard consulting-NDA shape allows pattern publication. Per industry NDA templates: confidential information typically excludes (a) public-knowledge, (b) independently developed, (c) information rightfully obtained from third parties. The technical pattern (PRO-303-style dual-path override, MAC 3x6 matrix) is a methodology layer that is arguably "independently developed by the founder" rather than client confidential, even if the specific column names are.
- Anonymization techniques for B2B enterprise data are well-established as a discipline. Data masking, k-anonymity, generalization, and field-mapping all apply at the field-study level (arXiv: Strategic Masking Techniques for B2B Enterprise Data).
Convergences and contradictions
Convergence: vault and web both confirm Nutrafol is already publicly named as an MG client with public outcome metrics (60% revenue / Unilever exit). The "is it possible to name the client" question is settled by MG's own published collateral.
Convergence: the technical pattern (MAC 3x6 matrix, PRO-303 override case study) is methodology the founder developed and applied across MG engagements. Methodology is independently developed; column names, table names, BRDs are client-confidential. The publishable artifact splits at exactly that line.
Contradiction: vault's MAC landing page build spec blocks ANY mention of "Mammoth", "Progress", "Nutrafol", "gold_opp_pipeline", "silver_fct_*" via grep audit. This is currently the safest posture, and it's stricter than NDA actually requires. The contradiction: the bet-architecture playbook treats the Progress engagement as the live MAC instrumentation that anonymized publishing is the goal of, but the landing-page spec blocks it. The spec is the right default for a public MAC page; the Sanity Check serialized field study is a different surface that could thread the needle.
Contradiction: MG itself publishes Nutrafol case-study collateral and brand attribution. RDCO publishing about working on a "well-known DTC hair-supplement brand with Magento + Snowflake + Segment that scaled through a 2022 acquisition" reads as Nutrafol to anyone who reads MG's collateral. Anonymization without explicit Nutrafol-permission is fragile — the persona-class reader will identify the brand within 60 seconds. The protection is methodology-focused, not identity-focused.
Synthesis for RDCO
The "anonymize a MG engagement into a serialized field study" question splits into three feasibility paths, ordered by risk:
Path 1: Fully synthetic field study, MG-inspired but not MG-derived (LOW RISK, HIGH PROVENANCE COST). Build a fictional company (e.g., "a Series B DTC supplements brand running Magento + Snowflake + dbt") with fictional table names and a fictional PRO-303-style override pattern. The pattern is real and load-bearing; the data is made up. Pro: zero NDA risk, no MG-permission asks, publishable today. Con: the credibility floor is lower (Mechanic 5 explicitly preferred case-study over synthetic exactly because synthetic reads as marketing). Footnote-disclosure required ("pattern observed across multiple analytics-engineering engagements; details synthesized").
Path 2: Anonymized field study built from MG patterns with explicit MG approval (MEDIUM RISK, HIGH CREDIBILITY). Same shape as Path 1 but the founder confirms with MG senior leadership (Dylan Cruise or Tom Clinton) that the methodology piece is fair game and the abstracted pattern doesn't reveal client-specific facts. Vault evidence suggests this conversation would land well: Dylan publicly framed the cc-wrapped agentic harness as the founder's "brainchild." That's permission-adjacent language. Pro: the founder can write with conviction, can use realistic numbers ("a 14-existing-tests-to-95-MAC-cells gap is typical in mid-market dbt projects" is a credible claim once a 30-second Dylan-conversation confirms anonymized-pattern publishing is fine). Con: requires one outreach action to Dylan/Tom, requires waiting for the response, requires founder discipline to honor the boundary they set.
Path 3: Explicit named-client case study with client permission (HIGH RISK, HIGHEST CREDIBILITY). Reach out directly to a Nutrafol or Progress contact, ask for explicit testimonial-style permission to write a published field study referencing them by name. Pro: highest credibility, opens the door to named-client testimonials. Con: the founder is mid-transition to phData; the optics of poking active MG client relationships for personal-brand content while leaving MG is awkward and could damage the standing return-offer Tom/Jeff explicitly extended. Almost certainly the wrong move in 2026; revisit in 2027 once the MG transition is past.
Recommended posture: Path 2. The founder has the social capital with Dylan and Tom to ask one direct question ("any concern if I write a Sanity Check field study on anonymized MAC patterns I built during the MG engagement, scrubbed of all client identifiers?"). The most likely answer is yes-with-the-obvious-guardrails. That answer materially upgrades every Sanity Check piece from Path 1 (synthetic) to Path 2 (methodology with real numbers from real engagements, anonymized).
Operational implication for Sanity Check serialization. Once Path 2 is unlocked, the candidate field-study arc looks like:
- Episode 1: The 14-to-95 gap. Anonymized MAC application showing the typical existing-tests-to-MAC-cells gap on a real dbt project. Hooks the persona on the diagnostic value.
- Episode 2: The PRO-303 pattern. Why conventional schema.yml testing misses dual-path overrides, with an anonymized PRO-303-style override example. Hooks on the bug-class-by-construction value.
- Episode 3: Severity tiers in production. How Stop/Pause/Go let all tests run without alert fatigue. Hooks on the operational-deployability angle.
- Episode 4: Cross-model reconciliation. Anonymized Aggregate-scope rules (gold↔gold reconciliation). Hooks on the audit-readiness value.
- Episode 5: The cc-wrapped harness pattern. Dylan's on-record characterization of the harness as transformative — this episode IS the MAC delivery-vehicle thesis, told as a real-world adoption story. (Requires explicit Dylan permission to quote.)
This is the case-study-version of Mechanic 5 that the practitioner-newsletter brief named as higher-credibility than the synthetic version. It's accessible at the cost of one outreach conversation.
Action recommendation for the founder: schedule the Dylan-or-Tom permission conversation within the first 30 days at phData (so the MG transition is cleanly past, but the relationships are still fresh). Frame as: "I'd like to write a Sanity Check field-study series on the MAC methodology I built across MG engagements, with full anonymization of client identifiers, code references, and BRD content. Want to confirm there's no concern from your side before I draft." Document the response in the vault. Path 2 unlocks.
Open follow-ups
- What's the exact text of the MG consulting-services contract on IP ownership for "methodology developed during engagement"? Worth surfacing before any field-study publication. (Internal-review doc may already have this.)
- Does the cc-wrapped harness IP boundary settlement explicitly cover authored content about the harness, or just the harness code itself? Sanity Check episode 5 depends on the answer.
- Has Nutrafol been mentioned in any Mammoth Growth-published material the founder personally authored or contributed to? If yes, the founder's name is already adjacent to Nutrafol in public — anonymization fiction is even thinner.
- What's the timing constraint on the metrongrowth.com rebrand? If MG is consolidating domains, the existing case studies may be migrating or disappearing — affects what's still publicly cite-able.
- Could the founder pre-clear a single canonical "anonymization protocol" with Dylan/Tom that applies to ALL future field-study episodes, rather than asking permission per episode? More efficient if relationship supports it.
Sources
Vault:
- [[~/rdco-vault/01-projects/mammoth-growth/2026-05-05-sendoff-testimonials.md]]
- [[~/rdco-vault/01-projects/mammoth-growth/index.md]]
- [[~/rdco-vault/01-projects/data-quality-framework/case-studies/2026-04-13-gold-opp-pipeline-mg-progress.md]]
- [[~/rdco-vault/01-projects/mac-landing/2026-05-05-build-spec.md]]
- [[~/rdco-vault/06-reference/research/2026-05-11-practitioner-newsletter-acquisition-tactics.md]]
- [[~/rdco-vault/06-reference/2026-04-30-rdco-bet-architecture-playbook.md]]
- [[~/rdco-vault/06-reference/internal-review-mg-harness-cc-wrapped-2026-04-13.md]]
- [[~/rdco-vault/01-projects/services-offering/2026-04-16-client-reporting-automation-one-pager.md]]
Web:
- Mammoth Growth Proof Page: https://www.mammothgrowth.com/proof
- Mammoth Growth Nutrafol Case Study (redirected): https://www.mammothgrowth.co.uk/case-study/nutrafol
- Datafold Nutrafol case study: https://www.datafold.com/case-study/nutrafol/
- Magecom Nutrafol case study: https://www.magecom.net/case-study/nutrafol
- arXiv: Strategic Masking Techniques for B2B Enterprise Data: https://arxiv.org/pdf/2312.03293
- Oneflow NDA for consulting template: https://oneflow.com/free-contract-templates/nda-for-consulting-template/